MTOR inhibition: A promising strategy for stabilization of atherosclerotic plaques

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 601-607

  Martinet, Wim ^a   De Loof, Hans ^a   De Meyer, Guido R Y ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Atherosclerosis; Autophagy; Drug eluting stent; Everolimus; MTOR; Rapamycin

Indexed keywords

ANTILIPEMIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EVEROLIMUS; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MICROTUBULE ASSOCIATED PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS; APOLIPOPROTEIN E; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOPHAGY; BARE METAL STENT; BILE ACID SYNTHESIS; BIORESORBABLE SCAFFOLD; BLOOD VESSEL WALL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEALING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IN-STENT RESTENOSIS; LIPID STORAGE; LIPOPHILICITY; MACROPHAGE; MACROPHAGE ACTIVATION; METAL STENT; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RNA INTERFERENCE; STENT THROMBOSIS; SYSTEMIC THERAPY; WOUND HEALING IMPAIRMENT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIODEGRADABLE IMPLANT; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DEFICIENCY; DRUG COMBINATION; DRUG EFFECTS; DRUG ELUTING STENT; DRUG INTERACTION; DRUG SCREENING; DYSLIPIDEMIAS; KNOCKOUT MOUSE; MOUSE; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; RABBIT; RUPTURE, SPONTANEOUS; SWINE; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; MACROPHAGES; METFORMIN; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; RABBITS; RECEPTORS, LDL; RUPTURE, SPONTANEOUS; SIROLIMUS; SWINE; TISSUE SCAFFOLDS; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES;

EID: 84896295961     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.01.040     Document Type: Review

References (69)

1. Tarantino G., Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med 2013, 45:348-356. 10.3109/07853890.2013.770333.
2. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293. 10.1016/j.cell.2012.03.017.
3. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. FEBS Lett 2010, 584:1287-1295. 10.1016/j.febslet.2010.01.017.
4. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. Amammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758. 10.1038/369756a0.
5. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168. 10.1016/j.molcel.2006.03.029.
6. Gangloff Y.G., Mueller M., Dann S.G., et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004, 24:9508-9516. 10.1128/MCB.24.21.9508-9516.2004.
7. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995, 76:412-417. 10.1161/01.RES.76.3.412.
8. Castro C., Campistol J.M., Sancho D., Sanchez-Madrid F., Casals E., Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 2004, 172:31-38. 10.1016/J.atherosclerosis.2003.09.003.
9. Pakala R., Stabile E., Jang G.J., Clavijo L., Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. JCardiovasc Pharmacol 2005, 46:481-486.
10. Baetta R., Granata A., Canavesi M., et al. Everolimus inhibits monocyte/macrophage migration invitro and their accumulation in carotid lesions of cholesterol-fed rabbits. JPharmacol Exp Ther 2009, 328:419-425. 10.1124/jpet.108.144147.
11. Zhao L., Ding T., Cyrus T., et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br J Pharmacol 2009, 156:774-785. 10.1111/j.1476-5381.2008.00080.x.
12. Beutner F., Brendel D., Teupser D., et al. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice. Atherosclerosis 2012, 222:337-343. 10.1016/j.atherosclerosis.2012.03.003.
13. -/- mice despite severe hypercholesterolemia. Atherosclerosis 2008, 198:39-48. 10.1016/j.atherosclerosis.2007.09.019.
14. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014. 10.1016/j.atherosclerosis.2007.05.026.
15. Kockx M.M., Cromheeke K.M., Knaapen M.W., et al. Phagocytosis and macrophage activation associated with hemorrhagic microvessels in human atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:440-446. 10.1161/01.ATV.0000057807.28754.7F.
16. Ma K.L., Ruan X.Z., Powis S.H., Moorhead J.F., Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007, 292:H2721-H2728. 10.1152/ajpheart.01174.2006.
17. Mathis A.S., Jin S., Friedman G.S., Peng F., Carl S.M., Knipp G.T. The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. JPharm Sci 2007, 96:209-222. 10.1002/jps.20751.
18. Basso M.D., Nambi P., Adelman S.J. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 2003, 35:3136-3138. 10.1016/j.transproceed.2003.10.050.
19. Laplante M., Sabatini D.M. Regulation of mTORC1 and its impact on gene expression at a glance. JCell Sci 2013, 126:1713-1719. 10.1242/jcs.125773.
20. Ma K.L., Varghese Z., Ku Y., et al. Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2010, 298:H1646-H1651. 10.1152/ajpheart.00492.2009.
21. Wang B.T., Ducker G.S., Barczak A.J., Barbeau R., Erle D.J., Shokat K.M. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U S A 2011, 108:15201-15206. 10.1073/pnas.1103746108.
22. Naoum J.J., Woodside K.J., Zhang S., Rychahou P.G., Hunter G.C. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 2005, 37:1880-1884. 10.1016/j.transproceed.2005.02.080.
23. Cheng C., Tempel D., Oostlander A., et al. Rapamycin modulates the eNOS vs. shear stress relationship. Cardiovasc Res 2008, 78:123-129. 10.1093/cvr/cvm103.
24. Goueffic Y., Potter-Perigo S., Chan C.K., et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis 2007, 195:23-30. 10.1016/j.atherosclerosis.2006.11.023.
25. Elloso M.M., Azrolan N., Sehgal S.N., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. AmJTransplant 2003, 3:562-569. 10.1034/j.1600-6143.2003.00094.x.
26. Martin K.A., Rzucidlo E.M., Merenick B.L., et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004, 286:C507-C517. 10.1152/ajpcell.00201.2003.
27. Chen W.Q., Zhong L., Zhang L., et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009, 156:941-951. 10.1111/j.1476-5381.2008.00102.x.
28. Hayashi S., Yamamoto A., You F., et al. The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol 2009, 175:2226-2234. 10.2353/ajpath.2009.090152.
29. Rodriguez A.E., Granada J.F., Rodriguez-Alemparte M., et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the prospective, randomized oral rapamycin in Argentina (ORAR II) study. JAm Coll Cardiol 2006, 47:1522-1529. 10.1016/j.jacc.2005.12.052.
30. Lavigne M.C., Grimsby J.L., Eppihimer M.J. Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of humancoronary artery smooth muscle cell proliferation, but not migration. JCardiovasc Pharmacol 2012, 59:165-174. 10.1097/FJC.0b013e31823a39c7.
31. Lightell D.J., Woods T.C. Relative resistance to mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors. Ochsner J 2013, 13:56-60.
32. Rodriguez A.E., Rodriguez-Granillo A.M., Antoniucci D., et al. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial. Catheter Cardiovasc Interv 2012, 80:385-394. 10.1002/ccd.23352.
33. Verheye S., Martinet W., Kockx M.M., et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. JAm Coll Cardiol 2007, 49:706-715. 10.1016/j.jacc.2006.09.047.
34. Croons V., Martinet W., Herman A.G., Timmermans J.P., De Meyer G.R.Y. Selective clearance of macrophages in atherosclerotic plaques by the protein synthesis inhibitor cycloheximide. JPharmacol Exp Ther 2007, 320:986-993. 10.1124/jpet.106.113944.
35. Wang X., Li L., Li M., et al. Knockdown of mTOR by lentivirusmediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E-deficient mice. Int J Mol Med 2013, 32:1215-1221. 10.3892/ijmm.2013.1494.
36. Brugaletta S., Garcia-Garcia H.M., Onuma Y., Serruys P.W. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. Expert Rev Med Devices 2012, 9:327-338. 10.1586/erd.12.17.
37. Onuma Y., Serruys P.W., Perkins L.E., et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010, 122:2288-2300. 10.1161/CIRCULATIONAHA.109.921528.
38. Serruys P.W., Ormiston J.A., Onuma Y., et al. Abioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009, 373:897-910. 10.1016/S0140-6736(09)60325-1.
39. Kharlamov A.N. New revolution in vascular interventional medicine: bioresorbable scaffolds for atheroregression. JVasc Med Surg 2013, 1:103. 10.4172/2329-6925.1000103.
40. Jabara R., Pendyala L., Geva S., Chen J., Chronos N., Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention 2009, 5(Suppl F):F58-F64. 10.4244/EIJV5IFA10.
41. Pallet N., Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013, 12:177-186. 10.1517/14740338.2013.752814.
42. Hoogeveen R.C., Ballantyne C.M., Pownall H.J., et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001, 72:1244-1250.
43. Deters M., Kirchner G., Koal T., Resch K., Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 2004, 49:30-37.
44. Tur M.D., Garrigue V., Vela C., et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 2000, 32:2783-2784. 10.1016/s0041-1345(00)01884-4.
45. Ai D., Chen C., Han S., et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. JClin Invest 2012, 122:1262-1270. 10.1172/JCI61919.
46. Sun W., Lee T.S., Zhu M., et al. Statins activate AMP-activated protein kinase invitro and invivo. Circulation 2006, 114:2655-2662. 10.1161/CIRCULATIONAHA.106.630194.
47. Wei Y.M., Li X., Xu M., et al. Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. Cell Physiol Biochem 2013, 31:925-937. 10.1159/000350111.
48. Barlow A.D., Nicholson M.L., Herbert T.P. Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms. Diabetes 2013, 62:2674-2682. 10.2337/db13-0106.
49. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643. 10.1126/science.1215135.
50. Stettler C., Allemann S., Wandel S., et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337:a1331 2008.
51. Zhou G., Myers R., Li Y., Chen Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. JClin Invest 2001, 108:1167-1174. 10.1172/JCI13505.
52. Ben Sahra I., Regazzetti C., Robert G., et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011, 71:4366-4372. 10.1158/0008-5472.CAN-10-1769.
53. Kalender A., Selvaraj A., Kim S.Y., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010, 11:390-401. 10.1016/j.cmet.2010.03.014.
54. Martinet W., Verheye S., De Meyer I., et al. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler Thromb Vasc Biol 2012, 32:1228-1235. 10.1161/ATVBAHA.112.245381.
55. Molas-Ferrer G., Soy-Muner D., Anglada-Martinez H., Riu-Viladoms G., Estefanell-Tejero A., Ribas-Sala J. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors. Nefrologia 2013, 33:297-300. 10.3265/Nefrologia.pre2013.Jan.11439.
56. Morelon E., Stern M., Israel-Biet D., et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001, 72:787-790.
57. Thaunat O., Beaumont C., Chatenoud L., et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005, 80:1212-1219.
58. Miriuka S.G., Rao V., Peterson M., et al. mTOR inhibition induces endothelial progenitor cell death. Am J Transplant 2006, 6:2069-2079. 10.1111/j.1600-6143.2006.01433.x.
59. Liu H.T., Li F., Wang W.Y., et al. Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. Tex Heart Inst J 2010, 37:194-201.
60. Camici G.G., Steffel J., Amanovic I., et al. Rapamycin promotes arterial thrombosis invivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J 2010, 31:236-242. 10.1093/eurheartj/ehp259.
61. Brattstrom C., Sawe J., Jansson B., et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit 2000, 22:537-544.
62. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011, 10:868-880. 10.1038/nrd3531.
63. Santulli G., Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics 2013, 14:1517-1526. 10.2217/pgs.13.143.
64. Turner R.C., Holman R.R., Stratton I.M., et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
65. Martin-Montalvo A., Mercken E.M., Mitchell S.J., et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013, 4:2192. 10.1038/ncomms3192.
66. Din F.V., Valanciute A., Houde V.P., et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012, 142:1504-1515. 10.1053/j.gastro.2012.02.050.
67. Strong R., Miller R.A., Astle C.M., et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 2008, 7:641-650. 10.1111/j.1474-9726.2008.00414.x.
68. Waksman R., Pakala R., Burnett M.S., et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 2003, 4:34-38. 10.1016/s1522-1865(03)00121-5.
69. Gadioli A.L., Nogueira B.V., Arruda R.M., et al. Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice. Braz J Med Biol Res 2009, 42:1191-1195. 10.1590/S0100-879X2009005000036.